Corcept Therapeutics price target raised to $76 from $65 at Truist

Truist analyst Joon Lee raised the firm’s price target on Corcept Therapeutics to $76 from $65 and keeps a Buy rating on the shares. The firm is “incrementally more positive” on the stock following the company’s “upbeat” non-deal roadshow last week, noting that the continued momentum in Korlym uptake over a decade post-launch is “impressive and difficult to ignore”, the analyst tells investors in a research note. The de-risked Phase 3 program for the next-gen relacorilant, with GRADIENT study topline data due in early Q4 – is also “reason to be positive” on Corcept, Truist added.